The WHO: Building a Permanent Pandemic Market
The WHO: Building a Permanent Pandemic Market In the face of a potentially industry-ending slew of patent cliffs, Big Pharma has begun acquiring biotechnology companies to stave off collapse. To get these drugs to market, the industry is pursuing the only solution left for their dying model: a full takeover of the WHO to capture the global regulatory system. BY MAX JONES Big Pharma must soon confront an industry-wide hazard that reaches magnitudes far greater than the typical concerns of corporate profit margins and business politics. Through years of industry consolidation, it has essentially made itself “too big to fail.” Only now, the model which it once could never fail within — that is, the practice of obtaining patent exclusivity over drugs that are approved through clinical trials and regulations — has become obsolete, even impossible, under the current conditions of the industry. In this new climate, the trials and regulations Big Pharma once successfully navigated ...